Literature DB >> 26341985

Potassium channels in pulmonary arterial hypertension.

Olivier Boucherat1, Sophie Chabot2, Fabrice Antigny3, Frédéric Perros3, Steeve Provencher2, Sébastien Bonnet2.   

Abstract

Pulmonary arterial hypertension (PAH) is a devastating cardiopulmonary disorder with various origins. All forms of PAH share a common pulmonary arteriopathy characterised by vasoconstriction, remodelling of the pre-capillary pulmonary vessel wall, and in situ thrombosis. Although the pathogenesis of PAH is recognised as a complex and multifactorial process, there is growing evidence that potassium channels dysfunction in pulmonary artery smooth muscle cells is a hallmark of PAH. Besides regulating many physiological functions, reduced potassium channels expression and/or activity have significant effects on PAH establishment and progression. This review describes the molecular mechanisms and physiological consequences of potassium channel modulation. Special emphasis is placed on KCNA5 (Kv1.5) and KCNK3 (TASK1), which are considered to play a central role in determining pulmonary vascular tone and may represent attractive therapeutic targets in the treatment of PAH.
Copyright ©ERS 2015.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26341985     DOI: 10.1183/13993003.00798-2015

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  22 in total

Review 1.  Pulmonary Hypertension and ATP-Sensitive Potassium Channels.

Authors:  Conor McClenaghan; Kel Vin Woo; Colin G Nichols
Journal:  Hypertension       Date:  2019-05-28       Impact factor: 10.190

2.  MicroRNA-mediated downregulation of K+ channels in pulmonary arterial hypertension.

Authors:  Aleksandra Babicheva; Ramon J Ayon; Tengteng Zhao; Jose F Ek Vitorin; Nicole M Pohl; Aya Yamamura; Hisao Yamamura; Brooke A Quinton; Manqing Ba; Linda Wu; Keeley S Ravellette; Shamin Rahimi; Francesca Balistrieri; Angela Harrington; Rebecca R Vanderpool; Patricia A Thistlethwaite; Ayako Makino; Jason X-J Yuan
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2019-09-25       Impact factor: 5.464

3.  Translational Advances in the Field of Pulmonary Hypertension. Translating MicroRNA Biology in Pulmonary Hypertension. It Will Take More Than "miR" Words.

Authors:  Hyung J Chun; Sébastien Bonnet; Stephen Y Chan
Journal:  Am J Respir Crit Care Med       Date:  2017-01-15       Impact factor: 21.405

4.  Pulmonary Vasculature Responsiveness to Phosphodiesterase-5A Inhibition in Heart Failure With Reduced Ejection Fraction: Possible Role of Plasma Potassium.

Authors:  Luca Monzo; Adrian Reichenbach; Hikmet Al-Hiti; Ivana Jurcova; Zuzana Huskova; Josef Kautzner; Vojtech Melenovsky
Journal:  Front Cardiovasc Med       Date:  2022-05-26

5.  Increased Smooth Muscle Kv11.1 Channel Expression in Pulmonary Hypertension and Protective Role of Kv11.1 Channel Blocker Dofetilide.

Authors:  Nataliia V Shults; Vladyslava Rybka; Yuichiro J Suzuki; Tinatin I Brelidze
Journal:  Am J Pathol       Date:  2019-12-12       Impact factor: 4.307

6.  BKCa Channel Activation Attenuates the Pathophysiological Progression of Monocrotaline-Induced Pulmonary Arterial Hypertension in Wistar Rats.

Authors:  Ana Paula Ferraz; Fernando A C Seara; Emanuelle F Baptista; Thais S Barenco; Thais B B Sottani; Natalia S C Souza; Ainá E Domingos; Raiana A Q Barbosa; Christina M Takiya; Marcos T Couto; Gabriel O Resende; Antonio C Campos de Carvalho; Cristiano G Ponte; Jose Hamilton M Nascimento
Journal:  Cardiovasc Drugs Ther       Date:  2020-11-27       Impact factor: 3.727

7.  KCNK3 Mutation Causes Altered Immune Function in Pulmonary Arterial Hypertension Patients and Mouse Models.

Authors:  James D West; Eric D Austin; Elise M Rizzi; Ling Yan; Harikrishna Tanjore; Amber L Crabtree; Christy S Moore; Gladson Muthian; Erica J Carrier; David A Jacobson; Rizwan Hamid; Peggy L Kendall; Susan Majka; Anandharajan Rathinasabapathy
Journal:  Int J Mol Sci       Date:  2021-05-09       Impact factor: 5.923

8.  The Prostacyclin Analogue, Treprostinil, Used in the Treatment of Pulmonary Arterial Hypertension, is a Potent Antagonist of TREK-1 and TREK-2 Potassium Channels.

Authors:  Kevin P Cunningham; Lucie H Clapp; Alistair Mathie; Emma L Veale
Journal:  Front Pharmacol       Date:  2021-06-29       Impact factor: 5.810

9.  Restoration of Vitamin D Levels Improves Endothelial Function and Increases TASK-Like K+ Currents in Pulmonary Arterial Hypertension Associated with Vitamin D Deficiency.

Authors:  Maria Callejo; Daniel Morales-Cano; Gema Mondejar-Parreño; Bianca Barreira; Sergio Esquivel-Ruiz; Miguel Angel Olivencia; Laura Moreno; Angel Cogolludo; Francisco Perez-Vizcaino
Journal:  Biomolecules       Date:  2021-05-26

Review 10.  DNA Damage and Pulmonary Hypertension.

Authors:  Benoît Ranchoux; Jolyane Meloche; Roxane Paulin; Olivier Boucherat; Steeve Provencher; Sébastien Bonnet
Journal:  Int J Mol Sci       Date:  2016-06-22       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.